Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III non-small cell lung cancer in Japan: A Multicenter Prospective Study (AYAME)

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer

Lung Cancer

Crespi V, Delcuratolo MD, Minuti G, Montrone M, Pilotto S, Roca E, Metro G, Leonetti A, Pelizzari G, Genova C, Olmetto E, Cortinovis D, Russo A, Pasello G, Bulotta A, Grossi F, Buosi R, Conte AD, Sini C, Greco C, Morabito A, Pignataro D, Pagano M, Gori S, Giannarelli D, Novello S, Passiglia F

doi: 10.1016/j.lungcan.2025.108576

Lung, Respiratory and Thoracic Cancer

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study

Lung Cancer

Sugisaka J, Fujimoto D, Tamiya M, Hata A, Matsumoto H, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Kijima T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Saito G, Miura S, Yamaguchi T, Daga H, Sakata S, Yamamoto N, Akamatsu H

doi: 10.1016/j.lungcan.2024.108056

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study

★ 3 Recommended by Dr Wolf-Dieter Janthur, Faculty Member

Ann Oncol

Lu S, Ahn MJ, Reungwetwattana T, Özgüroğlu M, Kato T, Yang JC, Huang M, Fujiki F, Inoue T, Quang LV, Sriuranpong V, Vicente D, Fuentes C, Chaudhry AA, Poole L, Armenteros Monterroso E, Rukazenkov Y, van der Gronde T, Ramalingam SS

doi: 10.1016/j.annonc.2024.08.2243

Lung, Respiratory and Thoracic Cancer

Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis

Eur J Cancer

Acker F, Reck M, Martin D, Rieken S, Heinzen S, Rost M, Aguinarte L, Schulte H, Serve H, Oellerich T, Sebastian M, Althoff FC

doi: 10.1016/j.ejca.2025.115266

Lung, Respiratory and Thoracic Cancer

Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group

Lung Cancer

Xenophontos E, Giaj Levra N, Durieux V, van Geffen WH, Grisay G, De la Pinta Alonso C, Arasanz H, Prisciandaro E, Ferrara R, Derks J, Von der Thusen J, Dickhoff C, Brandão M, Faivre-Finn C, Edwards J, Ruysscher D, Remon J, Dingemans AC, Berghmans T

doi: 10.1016/j.lungcan.2025.108671

Lung, Respiratory and Thoracic Cancer

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study

Lung Cancer

Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Huemer F, de Castro G Jr, Havel L, Bernabé Caro R, Losonczy G, Lee JS, Kowalski DM, Andric Z, Califano R, Veatch A, Gerstner G, Batus M, Morris S, Kaul M, Cuchelkar V, Li H, Danner BJ, Nabet BY, Liu SV

doi: 10.1016/j.lungcan.2024.107924

Lung, Respiratory and Thoracic Cancer

Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis

Lung Cancer

Fujisaki T, Miyauchi E, Kida G, Miura Y, Watanabe K, Ashinuma H, Tamiya M, Kikuchi H, Arai D, Takahashi S, Masuda K, Takigami A, Nagai Y, Miyawaki T, Tsubata Y, Nakao A, Masubuchi K, Nishiyama K, Watanabe S, Morita S, Maemondo M

doi: 10.1016/j.lungcan.2025.108597

Lung, Respiratory and Thoracic Cancer

Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study

Lung Cancer

Tambo Y, Sone T, Nishi K, Shibata K, Kita T, Araya T, Shirasaki H, Shimizu T, Yoneda T, Matsuoka H, Nanjo S, Koba H, Terada N, Ueda T, Nomura S, Murase Y, Yano S

doi: 10.1016/j.lungcan.2025.108422

Lung, Respiratory and Thoracic Cancer

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer

JAMA Oncol

Ricciuti B, Fusco F, Cooper A, Garbo E, Pecci F, Aldea M, Wang X, Mayoral Penalva M, Ginsberg M, Sholl LM, Nishino M, Di Federico A, Shaverdian N, Bott M, Santo V, Rendina E, Trisolini R, Ramella S, Gallina F, Melis E, Buglioni S, Minuti G, Landi L, Ugalde Figueroa PA, Shaw AT, Chaft J, Awad MM, Cappuzzo F

doi: 10.1001/jamaoncol.2025.1115

Related content

Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study

Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study

Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis

Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study

Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis

Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score ≥50 %: A multicenter observational study

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer